Bristol Myers celebrates a big win with FDA approval of $13B cardio drug mavacamten

Nicole DeFeudis

Editor

After getting hit with an FDA delay back in November, Bristol Myers Squibb is finally celebrating a win for mavacamten, the centerpiece of the company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers celebrates a big win with FDA approval of $13B cardio drug mavacamten

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

BioMarin turns to ex-Roche dealmaker James Sabry to build ‘next version’ of 27-year-old company

Purdue, Sacklers reach new $7.4B opioid settlement after SCOTUS rejection

As another Trump term gets underway, pharma advisors get comfortable with uncertainty

China's biotech boom is threatening US drugmakers' dominance

AbbVie partners with Neomorph in latest molecular glue deal

Fueling More Breakthroughs: Manufacturing Innovation to Expand Gene Therapy’s Reach

Bris­tol My­ers cel­e­brates a big win with FDA ap­proval of $13B car­dio drug mava­camten

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Bristol Myers celebrates a big win with FDA approval of $13B cardio drug mavacamten